Literature DB >> 10607261

Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy. The GEMHEP.

M Martinot-Peignoux1, F Roudot-Thoraval, I Mendel, J Coste, J Izopet, G Duverlie, C Payan, J M Pawlotsky, C Defer, M Bogard, V Gerolami, P Halfon, Y Buisson, B Fouqueray, P Loiseau, J Lamoril, J J Lefrere, P Marcellin.   

Abstract

The aim of this study was to investigate the following in a large population of French patients with chronic hepatitis C: the geographical distribution of hepatitis C virus (HCV) genotypes; the relationship between HCV genotypes and epidemiological characteristics; severity of the disease; and response to interferon (IFN) therapy. Data from 14 tertiary referral centres, corresponding to 1872 patients with chronic hepatitis C, were prospectively collected from 1989 to 1997. HCV genotyping was performed using the line probe assay (LiPA). HCV genotypes 1b, 3, 1a, 2, 4 and a mixed infection were found in 41%, 22%, 16%, 11%, 4% and 4% of our population, respectively. HCV genotype distribution was homogeneous, except for genotype 2 that was found more frequently in the southwest than in the other regions (21% vs 9.2%) (P=0.001). HCV distribution was associated with gender, age, and source and duration of infection. In multivariate analysis, these correlations were related to the source of infection, which was the only independent factor significantly associated with genotype (P=0.001). Genotype 1b was significantly more common in patients with cirrhosis, but in multivariate analysis cirrhosis was independently related to older age at exposure and longer duration of infection (P=0.001). A sustained response to IFN therapy was observed in 11% of patients infected with genotypes 1a or 1b vs 32% of those infected with genotypes 2 or 3 (P=0.001). This study shows that HCV genotype is mainly related to the source infection, but not to the intrinsic pathogenicity of HCV, and is a strong predictor of sustained response to therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10607261     DOI: 10.1046/j.1365-2893.1999.00187.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  21 in total

1.  Is chronic hepatitis C virus infection a risk factor for breast cancer?

Authors:  Dominique Larrey; Marie-Cécile Bozonnat; Ihab Kain; Georges-Philippe Pageaux; Eric Assenat
Journal:  World J Gastroenterol       Date:  2010-08-07       Impact factor: 5.742

2.  Assessment of viral loads in patients with chronic hepatitis C with AMPLICOR HCV MONITOR version 1.0, COBAS HCV MONITOR version 2.0, and QUANTIPLEX HCV RNA version 2.0 assays.

Authors:  M Martinot-Peignoux; V Le Breton; S Fritsch; G Le Guludec; N Labouret; F Keller; P Marcellin
Journal:  J Clin Microbiol       Date:  2000-07       Impact factor: 5.948

3.  Genotype distribution and molecular epidemiology of hepatitis C virus in blood donors from southeast France.

Authors:  Jean-François Cantaloube; Pierre Gallian; Houssam Attoui; Philippe Biagini; Philippe De Micco; Xavier de Lamballerie
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

4.  Clinical Profile and Response to Treatment with Pegylated Interferon α 2b and Ribavirin in Chronic Hepatitis C-A Reappraisal from a Tertiary Care Center in Northern India.

Authors:  Vinod K Dixit; Jayanta K Ghosh; Sangey C Lamtha; Pankaj Kaushik; Sundeep K Goyal; Manas K Behera; Neha Singh; Ashok K Jain
Journal:  J Clin Exp Hepatol       Date:  2014-06-18

5.  Evaluation of the VERSANT HCV RNA 3.0 assay for quantification of hepatitis C virus RNA in serum.

Authors:  Pascale Trimoulet; Philippe Halfon; Eric Pohier; Hacène Khiri; Geneviève Chêne; Hervé Fleury
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

6.  Psychological impact of chronic hepatitis C: comparison with other stressful life events and chronic diseases.

Authors:  Laurent Castera; Aymery Constant; Pierre-Henri Bernard; Victor de Ledinghen; Patrice Couzigou
Journal:  World J Gastroenterol       Date:  2006-03-14       Impact factor: 5.742

7.  Incident Hepatitis C Virus Genotype Distribution and Multiple Infection in Australian Prisons.

Authors:  Melanie R Walker; Hui Li; Suzy Teutsch; Brigid Betz-Stablein; Fabio Luciani; Andrew R Lloyd; Rowena A Bull
Journal:  J Clin Microbiol       Date:  2016-05-11       Impact factor: 5.948

8.  Epidemiological manifestations of hepatitis C virus genotypes and its association with potential risk factors among Libyan patients.

Authors:  Hana A Elasifer; Yossif M Agnnyia; Basher A Al-Alagi; Mohamed A Daw
Journal:  Virol J       Date:  2010-11-13       Impact factor: 4.099

9.  Factors influencing a low rate of hepatitis C viral RNA clearance in heroin users from Southern China.

Authors:  Rebecca-J Garten; Sheng-Han Lai; Jin-Bing Zhang; Wei Liu; Jie Chen; Xiao-Fang Yu
Journal:  World J Gastroenterol       Date:  2008-03-28       Impact factor: 5.742

10.  Hepatitis C virus (HCV) genotypes in the Caribbean island of Martinique: evidence for a large radiation of HCV-2 and for a recent introduction from Europe of HCV-4.

Authors:  Jenny Martial; Yoann Morice; Sylvie Abel; André Cabié; Christelle Rat; Frédéric Lombard; André Edouard; Serge Pierre-Louis; Philippe Garsaud; Odile Béra; Roger Chout; Emmanuel Gordien; Paul Deny; Raymond Césaire
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.